Starting January 1, the branded asthma inhaler Flovent will be discontinued by GSK, with an “authorized generic” version being offered instead. While the authorized generic is identical in function, it doesn’t appear to be covered as widely by insurers. This change is part of GSK’s strategy to avoid penalties associated with Medicaid rebates, as a legal change in January removes the cap on Medicaid rebates for drugs with significant price increases. GSK’s authorized generic is priced lower than branded Flovent, but insurance plans may not cover it, potentially causing disruptions for patients in the winter respiratory virus season. The strategy of discontinuing and offering an authorized generic is seen as a way for pharmaceutical companies to maintain profitability amid changing Medicaid rebate policies.
COVID-19 hospitalizations in the United States are increasing as a new omicron subvariant, referred to as EG.5 or…
The US Centers for Disease Control and Prevention is urging health care providers and consumers to stop using EzriCare Artificial Tears as it conducts an investigation into at least 55 infections in 12 states that have led to instances of permanent vision loss, hospitalization and one death. Source
More than half of US adults support ending the sale of all tobacco products, according to a new study led by researchers from the US Centers for Disease Control and Prevention, and nearly two-thirds said they support banning menthol cigarette sales. Source
Covid-19 has become the eighth most common cause of death among children in the United States, according to a study published Monday. Source